- Home
- ONFO vs BGLC Comparison
ONFO vs BGLC Comparison
Compare ONFO & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- BGLC
- Stock Information
- Founded
- ONFO 2018
- BGLC 2017
- Country
- ONFO United States
- BGLC Malaysia
- Employees
- ONFO N/A
- BGLC N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- BGLC Medical Specialities
- Sector
- ONFO Technology
- BGLC Health Care
- Exchange
- ONFO Nasdaq
- BGLC Nasdaq
- Market Cap
- ONFO 5.8M
- BGLC 5.8M
- IPO Year
- ONFO 2022
- BGLC N/A
- Fundamental
- Price
- ONFO $0.96
- BGLC $3.10
- Analyst Decision
- ONFO
- BGLC
- Analyst Count
- ONFO 0
- BGLC 0
- Target Price
- ONFO N/A
- BGLC N/A
- AVG Volume (30 Days)
- ONFO 9.2K
- BGLC 158.2K
- Earning Date
- ONFO 05-16-2025
- BGLC 05-15-2025
- Dividend Yield
- ONFO N/A
- BGLC N/A
- EPS Growth
- ONFO N/A
- BGLC N/A
- EPS
- ONFO N/A
- BGLC N/A
- Revenue
- ONFO $9,087,118.00
- BGLC $9,265,870.00
- Revenue This Year
- ONFO N/A
- BGLC N/A
- Revenue Next Year
- ONFO N/A
- BGLC N/A
- P/E Ratio
- ONFO N/A
- BGLC N/A
- Revenue Growth
- ONFO 65.97
- BGLC N/A
- 52 Week Low
- ONFO $0.61
- BGLC $2.01
- 52 Week High
- ONFO $1.88
- BGLC $8.40
- Technical
- Relative Strength Index (RSI)
- ONFO 43.22
- BGLC 49.12
- Support Level
- ONFO $0.98
- BGLC $3.13
- Resistance Level
- ONFO $1.02
- BGLC $5.07
- Average True Range (ATR)
- ONFO 0.04
- BGLC 0.49
- MACD
- ONFO 0.00
- BGLC -0.01
- Stochastic Oscillator
- ONFO 42.86
- BGLC 19.61
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.